| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $72,830,068 ) (Continued on the next page) |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32HD113384 | Developmental mechanisms specifying vagal innervation of organ targets | 000 | 3 | NIH | 1/9/2026 | $80,224 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 000 | 21 | NIH | 1/10/2026 | $10,875,343 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 006 | 21 | NIH | 1/27/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 005 | 21 | NIH | 1/26/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 004 | 21 | NIH | 1/25/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 21 | NIH | 1/24/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 002 | 21 | NIH | 1/23/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 001 | 21 | NIH | 1/22/2026 | $1 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 000 | 21 | NIH | 1/14/2026 | $17,863,384 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 000 | 21 | NIH | 1/14/2026 | $250,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 000 | 21 | NIH | 1/14/2026 | $500,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 21 | NIH | 1/24/2026 | $14,336,305 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA287013 | Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN) | 000 | 3 | NIH | 1/13/2026 | $1,346,937 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA286954 | NCI Cancer Screening Research Network: Coordinating and Communication Center | 000 | 3 | NIH | 1/15/2026 | $1,354,658 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 000 | 21 | NIH | 12/9/2025 | $833,373 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 000 | 21 | NIH | 1/23/2026 | $15,428,408 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA214057 | Developing CVD prediction models for women with early stage breast cancer | 000 | 6 | NIH | 1/19/2026 | $648,055 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35HL171556 | Promoting T cell reconstitution after hematopoietic cell transplantation | 000 | 3 | NIH | 2/9/2026 | $1,135,768 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 000 | 8 | NIH | 12/17/2025 | $362,340 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA240832 | Novel Approaches to CD33-Directed Radioimmunotherapy | 000 | 8 | NIH | 12/5/2025 | $557,099 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM162410 | Visualization of native chromatin-associated complexes to elucidate chromatin regulatory mechanisms | 000 | 1 | NIH | 2/9/2026 | $484,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA286450 | Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy | 000 | 3 | NIH | 2/17/2026 | $601,181 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL161037 | Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Cell Transplant Recipients | 000 | 6 | NIH | 2/12/2026 | $703,183 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA298383 | Providing nicotine replacement therapy to enhance the efficacy of a smoking cessation smartphone app for Hispanic adults | 000 | 2 | NIH | 2/9/2026 | $647,926 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA297681 | Statistical Methods for Precision Prevention | 000 | 2 | NIH | 12/5/2025 | $455,052 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA276308 | Transcriptional-translational conflict in bladder epithelial homeostasis and cancer | 000 | 4 | NIH | 12/10/2025 | $512,155 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA277133 | Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies | 000 | 4 | NIH | 12/10/2025 | $361,548 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA287573 | Interrogating roles for REST in small cell lung cancer therapy response and resistance | 000 | 3 | NIH | 12/8/2025 | $523,869 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA285227 | Rational Vaccine Design to prevent HIV-Associated Lymphoma | 000 | 3 | NIH | 1/30/2026 | $560,212 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA287476 | Interrogating a novel axis of tumor suppression in small cell lung cancer | 000 | 2 | NIH | 12/5/2025 | $494,025 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 6 | NIH | 1/15/2026 | $125,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI173199 | Breastmilk antibodies regulate neonatal immunity to the microbiota | 000 | 4 | NIH | 1/24/2026 | $648,715 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 000 | 21 | NIH | 12/16/2025 | $392,157 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | K99AI180649 | Regulatory T cell coordination of the mucosal NK cell response during viral infection | 001 | 2 | NIH | 1/29/2026 | $128,250 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32GM163369 | Deconvoluting disparate roles of DDX6 in translational control | 000 | 1 | NIH | 1/22/2026 | $75,052 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 21 | NIH | 1/24/2026 | $400,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32GM153148 | Investigating the chromatin landscape of complex tissues through cell-type-specific patterns | 000 | 3 | NIH | 1/19/2026 | $78,040 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R00AI171000 | Innate immune factors governing restriction of human coronaviruses | 000 | 3 | NIH | 1/20/2026 | $0 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R00AI171000 | Innate immune factors governing restriction of human coronaviruses | 000 | 3 | NIH | 1/20/2026 | $0 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 001 | 24 | NIH | 1/14/2026 | $0 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 000 | 24 | NIH | 12/12/2025 | $0 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | K23AI163343 | Cytomegalovirus-specific Immune Reconstitution after Hematopoietic Cell Transplantation in the Era of Modern Antiviral Prophylaxis | 000 | 5 | NIH | 11/18/2025 | $0 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MH132500 | Evaluating a Multilevel Communication Campaign to Increase HIV Vaccine Trial Enrollment | 000 | 3 | NIH | 11/17/2025 | -$164,538 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MH132500 | Evaluating a Multilevel Communication Campaign to Increase HIV Vaccine Trial Enrollment | 000 | 3 | NIH | 11/17/2025 | -$331,022 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MH140465 | Leveraging telehealth to optimize PrEP and PEP delivery at pharmacies in Kenya | 000 | 1 | NIH | 12/15/2025 | $0 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01MH140465 | Leveraging telehealth to optimize PrEP and PEP delivery at pharmacies in Kenya | 000 | 1 | NIH | 12/15/2025 | $0 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | D43CA260656 | Training in Cancer Genomics and Genomic Data Science | 000 | 4 | NIH | 12/1/2025 | $0 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U2CCA271873 | Breast-cancer focused biomarker characterization center employing targeted mass spec assays in a CLIA environment | 000 | 3 | NIH | 12/2/2025 | $0 |
| | 2026 | 2025 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U2CCA271902 | Biomarkers for optimizing risk prediction and early detection of cancers of the colon and esophagus | 000 | 4 | NIH | 2/5/2026 | $0 |
|
